The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)
- Registration Number
- NCT00990808
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will investigate the effect of MK0859 on lipoprotein metabolism in patients with dyslipidemia already on statin therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
- Patient's weight has been stable for at least 6 weeks
- Patient is in good health based on medical history, physical exam, and laboratory tests
- Patient has dyslipidemia
Exclusion Criteria :
- Patient has a history of stroke, seizures, or major neurological disorders
- Patient has a history of cancer
- Patient is currently taking any lipid-lowering medications or substances except for statins
- Patient consumes excessive amounts of alcohol or caffeine
- Patient has multiple and/or severe allergies to food or drugs
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Panel A anacetrapib Period 1: atorvastatin + placebo to MK0859; Period 2: atorvastatin + MK0859 Panel B anacetrapib Period 1: placebo to atorvastatin + placebo to MK0859; Period 2: MK0859 + placebo to atorvastatin
- Primary Outcome Measures
Name Time Method Difference in Production Rate (PR) and Fractional Catabolic Rate (FCR) of Low Density Lipoprotein (LDL) apoB100 following treatment with MK0859 and atorvastatin versus atorvastatin alone 12 weeks
- Secondary Outcome Measures
Name Time Method Difference in FCR of LDL apoB100 following treatment with MK0859 versus placebo 12 weeks